Latest filingSep 10, 2026Most recent Form 4
MGX
Metagenomi Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/10 to 09/10. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$510k3 sells
Net open-market-$510k3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period3transactions
- S · Open-market sells · dominant3 · 100%
Activity by reported role
A joint filing can contribute to multiple roles3transactions
- SR · dominant2 · 67%
- Chief financial officer1 · 33%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeWapnick PamelaCommon Stock · Direct
206,580Sep 08, 2026
Irish JianCommon Stock · Direct
375,393Sep 08, 2026
Wein MatthewCommon Stock · Direct
126,133Sep 08, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 10 → Sep 10
LessMore
Top insiders
By absolute net value across the selected period- IJ-$2.5k
- WP-$2.2k
- WM-$415
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
MGX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| MGX | Wein Matthew | SR | sale | 358 | -$41.4k | S | — | — | 09/10 | 09/08 |
| MGX | Irish Jian | SR | sale | 2.14k | -$247k | S | — | — | 09/10 | 09/08 |
| MGX | Wapnick Pamela | CFO | sale | 1.91k | -$221k | S | — | — | 09/10 | 09/08 |
Metagenomi Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Metagenomi Therapeutics, Inc.?
Wein Matthew, Irish Jian, Wapnick Pamela.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Wein Matthew reported a sale on Sep 08, 2026 valued at $41.4k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $5,107.39. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.